5th Oct 2005 15:38
Skyepharma PLC05 October 2005 For Immediate Release 5 October, 2005 SkyePharma PLC SkyePharma R&D Day LONDON, UK, 5 October 2005 - SkyePharma PLC (LSE: SKP, NASDAQ: SKYE) announcestoday that its R&D Day meetings, originally intended to be held in London on 26October and in New York on 27 October, are being rescheduled because of certainrestrictions imposed by the Rights Issue announced on 28 September. The Londonmeeting will now be held on Wednesday 25 January 2006 at The Brewery, ChiswellSt, London and will start at 0930. The New York meeting will be held on Thursday26 January at the St Regis Hotel, 2 East 55th Street, New York and will takeplace over lunch. Attendance is by invitation only but the meetings will bewebcast. Further details of the agenda for these meetings will be publishednearer the day. These meetings will provide an opportunity to gain an in-depth awareness andunderstanding of key products in our portfolio and pipeline and to meet membersof our senior management team. For further information please contact: SkyePharma PLC +44 207 491 1777 Michael Ashton, Chief Executive Officer Peter Laing, Director of Corporate Communications +44 207 491 5124 Sandra Haughton, US Investor Relations +1 212 753 5780 Buchanan Communications +44 207 466 5000 Tim Anderson / Mark Court / Rebecca Skye Dietrich Notes for editors: About SkyePharma SkyePharma develops pharmaceutical products benefiting from world-leading drugdelivery technologies that provide easier-to-use and more effective drugformulations. There are now eleven approved and marketed products incorporatingSkyePharma's technologies in the areas of oral, injectable, inhaled and topicaldelivery, supported by advanced solubilisation capabilities. For moreinformation, visit www.skyepharma.com. The securities to be issued in the Rights Issue have not been and will not beregistered under the Securities Act of 1933 and may not be offered or sold inthe United States absent registration or an appropriate exemption fromregistration requirements. This information is provided by RNS The company news service from the London Stock ExchangeRelated Shares:
SKP.L